DURECT Corporation Earnings Conference Call (Q4 2012)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Feb 28 Calls Today's Calls

Call Details DURECT Corporation Earnings Conference Call (Q4 2012) Scheduled to start Thu, Feb 28, 2013, 4:30 pm Eastern -- this event is ongoing now-- Listen to the ongoing live event audio stream About DURECT Corp (NasdaqGM:DRRX) Other Calls  DURECT Corporation focuses on the development of pharmaceutical products for pain, central nervous system disorders, cardiovascular disease, and other chronic diseases based on its proprietary drug formulations and delivery platform technologies. Its products include Remoxy, an oxycodone gelatin capsule for chronic pain, which is accepted as a new drug application; POSIDUR, a release formulation of bupivacaine that is under Phase III clinical trial for post operative pain; ELADUR, a transdermal bupivacaine patch, which is under Phase II clinical trial, provides continuous delivery of bupivacaine for up to three days from a single application, as well as for the treatment of pain associated with post-herpetic neuralgia; and TRANSDUR-Sufentanil, a proprietary transdermal sufentanil patch, which is under Phase II clinical trial, provides continuous delivery of sufentanil for a period of up to seven days from a single application. The company’s products also comprise oral controlled release opioid for pain that is under the Phase I clinical trial; and ORADUR-ADHD, a preclinical trial product targeting attention deficit hyperactivity disorder. It markets ALZET, the miniature implantable osmotic pumps and accessories for experimental research in mice, rats, and other laboratory animals. The company also develops and manufactures various biodegradable polymers based on lactide, glycolide, and caprolactone under the LACTEL brand for pharmaceutical and medical device clients, as well as conducts research and development of pharmaceutical products in collaboration with third party pharmaceutical and biotechnology companies. The company has strategic agreements with Alpharma Ireland Limited; Nycomed Danmark, ApS; Pain Therapeutics, Inc.; Endo Pharmaceuticals Inc; Curaxis Pharmaceutical Corporation; ALZA Corporation; EpiCept Corporation; NeuroSystec Corporation; and King Pharmaceuticals, Inc. DURECT Corporation was founded in 1998 and is based in Cupertino, California. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings